National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 2 of 2 Research Studies DisplayedTrivedi LU, Alvarez CA, Mansi IA
Association of statin therapy with risk of epilepsy in 2 propensity score-matched cohorts.
The objective of this study was to examine the association between statin use and epilepsy risk in a general population and in a healthy population (individuals with no severe comorbidities). The study did not demonstrate a significant beneficial or deleterious effect of statin use on risk of being diagnosed with epilepsy. The authors assert that clinicians should not withhold statins, whenever indicated, in patients with epilepsy.
AHRQ-funded; HS022418.
Citation: Trivedi LU, Alvarez CA, Mansi IA .
Association of statin therapy with risk of epilepsy in 2 propensity score-matched cohorts.
Ann Pharmacother 2018 Jun;52(6):546-53. doi: 10.1177/1060028018756650..
Keywords: Medication, Medication: Safety, Adverse Drug Events (ADE), Adverse Events, Cardiovascular Conditions, Neurological Disorders, Risk
Vouri SM, Schootman M, Strope SA
Differential prescribing of antimuscarinic agents in older adults with cognitive impairment.
The objective of this study was to describe the use of oral oxybutynin versus other antimuscarinics in older adults with documented cognitive impairment. Patients with cognitive impairment were 5 percent more likely to initiate another antimuscarinic versus oral oxybutynin. The proportion of patients with cognitive impairment initiated on oral oxybutynin increased from 24.1 percent in 2008 to 41.1 percent in 2011.
AHRQ-funded; HS019455.
Citation: Vouri SM, Schootman M, Strope SA .
Differential prescribing of antimuscarinic agents in older adults with cognitive impairment.
Drugs Aging 2018 Apr;35(4):321-31. doi: 10.1007/s40266-018-0531-9.
.
.
Keywords: Adverse Drug Events (ADE), Elderly, Medication, Neurological Disorders